Iatrogenic immunosuppression with biologics in MS: expecting the unexpected?
Olaf
O
Stüve
Heinz
H
Wiendl
D000818:Animals; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D002986:Clinical Trials as Topic; D006801:Humans; D007049:Iatrogenic Disease; D007108:Immune Tolerance; D039441:Integrin alpha4 / Q000378:metabolism; D007968:Leukoencephalopathy, Progressive Multifocal / Q000139:chemically induced; D008297:Male; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy*; D000069442:Natalizumab; D012306:Risk; D014122:Toxoplasma; D014126:Toxoplasmosis, Ocular / Q000209:etiology*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069442:Natalizumab; D039441:Integrin alpha4